COMMUNIQUÉS West-GlobeNewswire

Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?
21/02/2025
AMSTERDAM, 21 févr. 2025 (GLOBE NEWSWIRE) -- Une nouvelle étude de Teva Pharmaceuticals Europe révèle que 46 % des médicaments génériques figurant sur la liste des médicaments essentiels de l’UE sont fournis par un seul [...]
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
21/02/2025
REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be [...]
Nusano Named “Researcher of the Year” at Inaugural Best of BioHive Awards
21/02/2025
WEST VALLEY CITY, Utah, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company committed to bringing supply stability and innovation to radioisotope markets, was named “Researcher of the Year” at the inaugural Best [...]
Philips publishes its Annual Report 2024
21/02/2025
February 21, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2024. Philips’ Annual Report 2024 will be on the agenda of the [...]
Change to the Executive Leadership Team
21/02/2025
Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Ester Baiget, President & [...]
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
21/02/2025
In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® ( ustekinumab ) and has granted a provisional determination of [...]
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
21/02/2025
In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® (ustekinumab) and has granted a provisional determination of [...]
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
21/02/2025
In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® (ustekinumab) and has granted a provisional determination of [...]
Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease
21/02/2025
Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board Director Seasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ammonia scavenger [...]
White Paper: Polish Presidency of the Council of the European Union 2025. Healthcare Policy Recommendations - A Unique Publication from the Institute for Social Policy Development Now Available
21/02/2025
WARSAW, Poland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The White Paper was unveiled on 21 February 2025 at the Medical University of Warsaw during the Health and Security for the Future conference organised by the Institute [...]
Philips and Mass General Brigham announce collaboration to improve patient care with live AI-powered insights
21/02/2025
February 21, 2025 Integrating advanced data analytics into clinical practice to improve patient care Amsterdam, The Netherlands and Cambridge, MA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health [...]
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
20/02/2025
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its [...]
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025
20/02/2025
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
NewGen Issues Clarification on Press Release Titled “NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director” dated February 20, 2025
20/02/2025
BANGKOK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”) today issued a clarification that, in the press release titled “NewGen Receives Continued Nasdaq Listing [...]
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
20/02/2025
RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by [...]
Brighter Strides ABA Expands Services with New Clinic Opening in Maryland
20/02/2025
Providing Compassionate, Individualized ABA Therapy for Children with Autism Catonsville, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Brighter Strides ABA is proud to announce the grand opening of its newest clinic in [...]
AMN Healthcare Announces Fourth Quarter and Full Year 2024 Results
20/02/2025
Quarterly revenue of $735 million; GAAP loss of ($4.90)/share and adjusted EPS of $0.75 DALLAS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent [...]
Globus Medical Reports Fourth Quarter and Full Year 2024 Results
20/02/2025
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, [...]
Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer
20/02/2025
PMD-026 is a first-in-class and best-in-class pan-RSK inhibitor Favorable mPFS demonstrated in Phase 1/1b as a monotherapy in RSK2-high metastatic breast cancer patients. SAN DIEGO and VANCOUVER, British Columbia, Feb. [...]

Pages